Marie Beauséjour, François Vaillancourt, Marie-Yvonne Akoume, Anita Franco, Stefan Parent, Hubert Labelle, Julie Joncas, Frédérique Desbiens-Blais, Jean-Marc Mac-Thiong, Marjolaine Roy-Beaudry, Carl-Éric Aubin, Alain Moreau


August 2020, pp 1 - 7 Original Article Read Full Article 10.1007/s00586-020-06579-1

First Online: 29 August 2020

Purpose

Bracing is the treatment of choice for idiopathic scoliosis (IS), unfortunately factors underlying brace response remain unknown. Clinicians are currently unable to identify patients who may benefit from bracing, and therefore, better molecular stratification is critically needed. The aim of this study is to evaluate IS patient outcomes at skeletal maturity in relation to biological endophenotypes, and determine specific endophenotypes associated to differential bracing outcomes. This is a retrospective cohort with secondary cross-sectional comparative studies.

Methods

Clinical and radiological data were collected from 563 IS patients, stratified into biological endophenotypes (FG1, FG2, FG3) based on a cell-based test. Measured outcomes were maximum Cobb angle at skeletal maturity, and if severe, spinal deformity (≥ 45°) or surgery was attained. Treatment success/failure was determined by standard progression thresholds (Cobb ≥ 45° or surgery; Cobb angle progression ≥ 6°). Multivariable analyses were performed to evaluate associations between endophenotypes and clinical outcome.

Results

Higher Cobb angles at maturity for FG1 and FG2 patients were observed (p = 0.056 and p = 0.05), with increased likelihood of ≥ 45° and/or surgery for FG1 (OR = 2.181 [1.002–4.749] and FG2 (OR = 2.141 [1.038–4.413]) compared to FG3. FG3 was 9.31 [2.58–33.61] and 5.63 [2.11–15.05] times more likely for bracing success at treatment termination and based on the

Conclusion

Associations between biological endophenotypes and outcomes suggest differences in progression and/or bracing response among IS patients. Outcomes were most favorable in FG3 patients. The results pave the way for establishing personalized treatments, distinguishing who may benefit or not from treatment.


Read Full Article